Fierce Pharma July 18, 2022
Fraiser Kansteiner

The genesis of a small molecule drug is often an international affair. The medication might begin its life at an active pharmaceutical ingredient (API) manufacturing facility in Puerto Rico, then stop off for formulation in the Netherlands before going through packaging steps in Greece, China, Japan or the U.S. Along the way, the production process gobbles up myriad consumables and raw materials from an even more diverse geographic spread.

All told, pharmaceutical supply chains have proven remarkably resilient during the COVID-19 pandemic. Thanks to regulatory flexibility, increased government cooperation and some good old-fashioned industry elbow grease, biopharma has largely avoided disruptions like those plaguing the semiconductor-starved consumer electronics sector.

But that’s not to say drugmakers’ supply chains...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Supply Chain, Survey / Study, Technology, Trends
Clearing The Crux: Five Paths To Achieve Health Policy Change In 2025
Proposed tariffs threaten biotech supply chain, innovation, BIO survey warns
The Supply Chain Hack: AI, Data And Real-Time Insights
Your New Creative Supply Chain: 5 Takeaways On AI And Marketing Content
Hospitals Face Mounting Supply Chain Crisis, Survey Reveals

Share This Article